RESUMO
We performed an uterotrophic assay, the Hershberger assay, and a 28-day repeated-dose toxicity study (enhanced OECD test guideline No. 407) of 4,4 -[1-[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl]ethylidene]bis[phenol] based on the OECD draft protocols. In the uterotrophic assay, female SD rats were subcutaneously injected with the chemical at doses of 0, 100, 300, and 1,000 mg/kg on each of 3 days from postnatal day 20 to day 22, and the uterine weight of rats given the 1,000 mg/kg dose of the test chemical plus ethinyl estradiol decreased. In the Hershberger assay, the test chemical was orally administered at doses of 0, 100, 300, and 1,000 mg/kg day to castrated male SD rats for ten consecutive days beginning on postnatal day 56, and no changes were observed. On the other hand, when the test chemical was orally administered at doses 0, 100, 300, and 1,000 mg/kg day for at least 28 days, a decrease in LH values in rats of both sexes and a decrease in FSH and estradiol values in female rats were detected in the 1,000 mg/kg group, and abnormal estrous cycles, uterine glandular atrophy, persistence of ovarian corpora lutea, vaginal epithelial mucification, and mammary glandular hyperplasia were also observed in one female rat in the 1,000 mg/kg group. Therefore, the uterotrophic assay used in this study showed that the chemical has the estrogen-antagonist properties, and some potentially endocrine-mediated effects were detected in growing rats based on the results of the enhanced OECD test guideline No. 407. However, the changes were observed in rats given a high dose of the chemical, 1,000 mg/kg day.
Assuntos
Alcenos/toxicidade , Antagonistas de Estrogênios/toxicidade , Fenóis/toxicidade , Alanina Transaminase/sangue , Animais , Bioensaio , Glicemia/análise , Proteínas Sanguíneas/análise , Colesterol/sangue , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Hormônio Luteinizante/sangue , Masculino , Contagem de Plaquetas , Ratos , Ratos Endogâmicos , Testes de Toxicidade , Triglicerídeos/sangue , Útero/efeitos dos fármacos , Útero/crescimento & desenvolvimento , Útero/patologiaRESUMO
We performed a 28-day repeated-dose toxicity study of diethylphthalate based on the draft protocol of the "Enhanced OECD Test Guideline 407" to investigate whether it has endocrine-mediated properties according to this assay. Diethylphthalate was orally administered to SD rats at doses of 0, 40, 200, and 1,000 mg/kg/day for at least 28 days, but no endocrine-mediated effects were detected based on any of the parameters examined, suggesting that diethylphthalate does not possess endocrine properties according to this assay.
Assuntos
Guias como Assunto , Ácidos Ftálicos/toxicidade , Plastificantes/toxicidade , Administração Oral , Medula Suprarrenal/efeitos dos fármacos , Medula Suprarrenal/patologia , Animais , Coagulação Sanguínea/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Fidelidade a Diretrizes , Intubação Gastrointestinal , Rim/efeitos dos fármacos , Rim/patologia , Masculino , Tamanho do Órgão , Tempo de Tromboplastina Parcial , Ácidos Ftálicos/administração & dosagem , Plastificantes/administração & dosagem , Ratos , Ratos Sprague-Dawley , Fatores Sexuais , Micção/efeitos dos fármacosRESUMO
We performed a 28-day repeated-dose toxicity study of di(2-ethylhexyl)adipate (DEHA) based on the draft protocol of the "Enhanced OECD Test Guideline 407" to investigate whether it has endocrine-mediated properties according to this assay. DEHA was orally administered to SD rats at doses of 0, 40, 200 and 1,000 mg/kg/day for at least 28 days, and disturbance of the estrous cycle and increased ovarian follicle atresia were detected in the 1,000 mg/kg group.
